Kyle Jenne

Bio:

Kyle has extensive experience in building commercial capabilities and organizations from the ground up - most recently, spearheading Ionis' first wholly owned launch for TRYNGOLZA. Throughout his career, he has supported go-to market strategies in multiple therapeutic areas including neurology, and he can speak to the opportunities and challenges of M&A in this space -- for example, knowing how or when to find a partner vs. go alone, how to find synergies between companies, how to work across geographies and cultures, etc. Kyle also brings a unique background as a former athletics coach, which has shaped his philosophies and approach to leading his team and driving success. His full bio is below my signature for your reference. 

As background, Ionis focuses on discovering, developing, and commercializing RNA-targeted medicines to treat serious diseases. Its focus areas include neurology, cardiology and other areas of high patient need. Ionis has a long legacy in neurology (the company developed Spinraza) and expansive pipeline in hard-to-treat neurological diseases.